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DC COVID-19 STATS THROUGH MAY 25

https://coronavirus.dc.gov/page/coronavirus-data
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ICU Bed Capacity D.C.
5/24/2020
33%
67%

Occupied

Available

Ventilator Capacity D.C
5/24/2020
54% 46%

In Use

Available

Thhe Virginia Hospital & Healthcare Association has launched an online dashboard of currently hospitalized patients with
COVID-19, available beds, and other resources.
The Maryland Emergency Management Agency also maintains a COVID-19 dashboard based on data released by the
Governor’s office and the Maryland Department of Health.

Highlights This Week
● The US continues to reopen despite many jurisdictions not yet meeting
“Gating Criteria.” CDC published guidance on how to do so as safely as
possible for multiple sectors; businesses, schools, etc.
● DC is considering reopening in the near future but local data have not yet
shown the recommended sustained decrease in community spread.
● Remdesivir trial early data was published and suggests survival benefit for
very sick patients. But given the high mortality despite the use of
remdesivir the authors conclude, “it is clear that treatment with an antiviral
drug alone is not likely to be sufficient. Future strategies should evaluate
antiviral agents in combination with other therapeutic approaches or
combinations of antiviral agents to continue to improve patient
outcomes…”
● Increasing evidence of childhood and adolescent Covid-19 disease is
being reported largely associated with infants and those over 15 years and
with co-morbidities.
● CDC has established a case definition for Multisystem Inflammatory
Syndrome in Children (MIS-C) Associated with Coronavirus Disease
2019 and recommends reporting all cases.
● Korean CDC investigation of re-positive cases revealed no evidence of
infectivity. Based on the data, they have updated their protocols to
eliminate post-isolation management including testing.
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CLINICAL KNOWLEDGE
● Diagnostics
Title: Findings from Investigation and analysis of re -positive cases
Publisher: Korean CDC
Publication Date: May 19, 2020
URL: https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030
Key Takeaway: Based on active monitoring, epidemiological investigation, and laboratory
testing of re-positive cases and their contacts, no evidence was found that indicated
infectivity of re-positive cases:
- Of the 447 re-positive cases as of 15 May, epidemiological investigation was conducted
on 285 cases and laboratory analysis on 108 cases. (*473 as of 18 May)
- From monitoring of 790 contacts of the 285 re-positive cases, no case was found that was
newly infected solely from contact with re-positive cases during re-positive period.
- Virus isolation in cell culture of respiratory samples of 108 re-positive cases, all result
was negative (i.e. virus not isolated).
- Of the 23 re-positive cases from which the first and the second serum samples were
obtained, 96% were positive for neutralizing antibodies.
Based on these data, the Korean CDC has updated their protocols to conduct no
additional tests for cases that have been discharged from isolation.

Title: Variation in False -Negative Rate of Reverse Transcriptase Polymerase Chain
Reaction–Based SARS-CoV-2 Tests by Time Since Exposure
Publisher: Annals of Internal Medicine
Publication Date: May 13, 2020
URL: https://www.acpjournals.org/doi/10.7326/M20-1495
Key Takeaway: This retrospective modeling study demonstrates the potentially high rate of
false negativity of RT-PCR in the pre-symptomatic period of SARS-CoV-2 infection. If
confirmed, this would reduce the predictive value of asymptomatic testing as a public health
strategy (such as in a population health screening program).
Over the 4 days of infection before the typical time of symptom onset (day 5), the probability
of a false-negative result in an infected person decreases from 100% (95% CI, 100% to
100%) on day 1 to 67% (CI, 27% to 94%) on day 4. On the day of symptom onset, the
median false-negative rate was 38% (CI, 18% to 65%). This decreased to 20% (CI, 12% to
30%) on day 8 (3 days after symptom onset) then began to increase again, from 21% (CI,
13% to 31%) on day 9 to 66% (CI, 54% to 77%) on day 21.

Title: Viral and host factors related to the clinical outcome of COVID-19
Publisher: Nature
Publication Date: May 20, 2020
URL: https://www.nature.com/articles/s41586-020-2355-0_reference.pdf
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Key Takeaway: Genomic sequences of SARS-CoV-2 assembled from 112 quality samples
together with sequences in the GISAID showed a stable evolution and suggested two major
lineages during the early phase of the outbreak in Wuhan although they exhibited similar
virulence and clinica l outcomes. The determinants of disease severity seemed to stem mostly
from host factors such as age, lymphocytopenia, and its associated cytokine storm, whereas
viral genetic variation did not significantly affect the outcomes. Of note, this study only
examined samples collected from China January-February. Other studies have shown more
genetic diversity in the virus, as would be expected.

● Therapeutics
Title: Remdesivir for the Treatment of Covid-19 — Preliminary Report
Publisher: NEJM
Publication Date: May 22, 2020
URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home
Key Takeaway: This is the published data from a double-blind, randomized, placebocontrolled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence
of lower respiratory tract involvement. Patients received either remdesivir or placebo for up
to 10 days. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to
placebo) show that those who received remdesivir had a median recovery time of 11 days, as
compared with 15 days in those who received placebo with the estimates of mortality by 14
days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95%
CI, 0.47 to 1.04). Serious adverse events were reported for a high percentage of both groups.
The authors conclude that the findings support the use of remdesivir for patients who are
hospitalized with Covid-19 and require supplemental oxygen therapy. But, given high
mortality despite the use of remdesivir, “it is clear that treatment with an antiviral drug alone
is not likely to be sufficient. Future strategies should evaluate antiviral agents in combination
with other therapeutic approaches or combinations of antiviral agents to continue to improve
patient outcomes in Covid-19.”

Title: Convalescent plasma or hyperimmune immunoglobulin for people with COVID19: A rapid review
Publisher: Cochrane Database of Systematic Reviews
Publication Date: May 14, 2020
URL: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600/full
Key Takeaway: Review of 8 available studies on convalescent plasma. Six reported on
clinical outcomes and all 6 showed improvement as measured by need for respiratory
support. However, all 8 studies were poor quality (not randomized, no controls) and their
results could be related to the natura l progression of the disease, other treatments that the
participants received, or to convalescent plasma. Highlights need for further investigation: 48
ongoing studies: 47 evaluating convalescent plasma and 1 evaluating hyperimmune
immunoglobulin, of which 22 are randomized.
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Title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV
antibody
Publisher: Nature
Publication Date: May 18, 2020
URL: https://www-nature-com.proxygw.wrlc.org/articles/s41586-020-2349-y#article-info
Key Takeaway: Important for potential for vaccine development, multiple monoclonal
antibodies targeting SARS-CoV-2 spike gylcoprotein were identified from memory B cells
of an individual who was infected with SARS-CoV in 2003. Using cryo-electron microscopy
and binding assays, one antibody, named S309, was found to potently neutralize SARS-CoV2 by engaging the S receptor-binding domain.

Title: Myth Busters: Dietary Supplements and COVID-19.
Publisher: Annals of Pharmacotherapy
Publication Date: May 12, 2020
URL: https://journals.sagepub.com/doi/pdf/10.1177/1060028020928052
Key Takeaway: This article reviews theoretical mechanisms and evidence related to efficacy
and safety of select supplements in the setting of COVID-19, including vitamin C, vitamin D,
zinc, elderberry, and silver. Evidence evaluating these supplements in COVID-19 patients is
lacking, and providers and patients should not rely on dietary supplements to prevent or treat
COVID-19.
●

Critical Care
Title: Is the Prone Position Helpful During Spontaneous Breathing in Patients With
COVID-19?
Publisher: JAMA
Publication Date: May 15, 2020
URL: https://jamanetwork.com/journals/jama/fullarticle/2766290
Key Takeaway: Two studies are discussed in this editorial comment:
Study 1: 24 patients with acute hypoxemic respiratory failure and infiltrates on chest CT
scans, 6 of 15 patients who tolerated prone position showed a mean (SD) increase in Pa O2 of
more than 20% from baseline (74 [16] to 95 [28] mm Hg; P = .006) but 3 patients returned to
baseline Pa O2 after supination.
Study 2: Awake patients with mild and moderate ARDS. Proned in 3 hour sessions, median
of 2 NIV sessions. 12 of 15 had improved oxygenation (Pa O 2 :FiO 2 100 to 122) and
respiratory rate (28 /min to 24 /min) during and for 1 hour after NIV session. At 14 days, 1
patient was intubated and 1 other died.
Conclusion: many but not all patients with hypoxemic respiratory failure tolerate the prone
position while awake, breathing spontaneously or while receiving NIV. Among patients who
tolerated a session of prone positioning, improvement in oxygenation and decrease in
respiratory rate occurred. The effects were transient, and respiratory rates and oxygenation
often returned to baseline after supination.
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● Obstetrics & Gynecology
Title: Placental Pathology in COVID-19
Publisher: American Journal of Clinical Pathology
Publication Date: May 22, 2020
URL: https://academic.oup.com/ajcp/advance-article/doi/10.1093/ajcp/aqaa089/5842018
Key Takeaway: Sixteen placentas from patients with severe acute respiratory syndrome
from COVID-19 were examined (15 with live birth in the third trimester, 1 delivered in the
second trimester after intrauterine fetal demise). Relative to controls, COVID-19 placentas
show increased prevalence of decidual arteriopathy and other features of MVM, a pattern of
placental injury reflecting abnormalities in oxygenation within the intervillous space
associated with adverse perinatal outcomes. Only 1 COVID-19 patient was hypertensive
despite the association of MVM with hypertensive disorders & preeclampsia. Changes may
reflect a systemic inflammatory or hypercoagulable state influencing placental physiology.

Title: Clinical Implications of Universal Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) Testing in Pregnancy
Publisher: Obstetrics & Gynecology
Publication Date: May 19, 2020
URL:
https://journals.lww.com/greenjournal/Citation/9000/Clinical_Implications_of_Universal_Se
vere_Acute.97343.aspx
Key Takeaway: Pregnant women with SARS-CoV-2 infection on admission do not seem to
be reliably identified using symptom screening alone. Observed SARS-CoV-2 infection
prevalence identified with universal screening (3.6%, 95% CI 2.3–5.4%) is sixfold higher
than prevalence rates based on reported rates for our county (0.6%) during this period.

● Pediatrics
Title: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with
Coronavirus Disease 2019 (COVID-19)
Publisher: CDC Health Alert Network
Publication Date: May 14, 2020
URL:
https://emergency.cdc.gov/han/2020/han00432.asp?fbclid=IwAR0uAXSaCVsqwUgU1gddC
E96m2a-Or31Zhxx9GD0WlDAgF0GGcYJuNfH_N0
Key Takeaway: Centers for Disease Control and Prevention (CDC) issued a Case
Definition for Multisystem Inflammatory Syndrome in Children (MIS-C):
•An individual aged <21 years presenting with fever (i), laboratory evidence of
inflammation (ii), and evidence of clinically severe illness requiring hospitalization,
with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic,
gastrointestinal, dermatologic or neurological); AND
•No alternative plausible diagnoses; AND
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•Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen
test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms :
i Fever >38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours
ii Including, but not limited to, one or more of the following: an elevated C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, ddimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated
neutrophils, reduced lymphocytes and low albumin
Additional comments
•Some individuals may fulfill full or partial criteria for Kawasaki disease but should be
reported if they meet the case definition for MIS-C
•Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection
CDC recommends healthcare providers report any patient who meets the case definition to
local, state, and territorial health departments to enhance knowledge of risk factors,
pathogenesis, clinical course, and treatment of this syndrome.
Title: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARSCoV-2 epidemic: An observational cohort study
Publisher: The Lancet
Publication Date: May 13, 2020
URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31103X/fulltext?fbclid=IwAR3FTBsNWiH600V6V1ByqDS1qBRyfKcNgRbofhbW0ytMuxye0U6As9ig2g
Key Takeaway: This reports a 30-fold increased incidence of Kawasaki-like disease in
Italy. Children diagnosed after the SARS-CoV-2 epidemic who showed evidence of immune
response to the virus were older, had a higher rate of cardiac involvement, and features of
macrophage activation syndrome. The authors suggest similar outbreak of Kawasaki-like
disease is expected in countries involved in the SARS-CoV-2 epidemic.
Title: Outbreak of Kawasaki disease in children during COVID-19 pandemic: A
prospective observational study in Paris, France . ****Preprint****
Publisher: medrXiv
Publication Date: May 14, 2020
URL: https://www.medrxiv.org/content/10.1101/2020.05.10.20097394v1
Key Takeaway: Not peer-reviewed. This study is currently the largest cohort reported on
these cases in which the diagnosis of Kawasaki disease (KD) was based on the criteria of the
American Heart Association for complete and incomplete KD and the criteria proposed by
Kanegaye et al. were used for the diagnosis of KD shock syndrome (KDSS). A total of 17
children were admitted for KD over an 11-day period. Eleven patients presented with KDSS
requiring intensive care support, and 12 had myocarditis. All children had marked
gastrointestinal symptoms at the early stage of illness and high levels of inflammatory
markers. Fourteen patients (82%) had evidence of recent SARS-CoV-2 infection (positive
RT-PCR 7/17, positive IgG antibody detection 14/16). All pat ients received
immunoglobulins and some received corticosteroids (5/17). The clinical outcome was
favorable in all patients.
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Compared to past descriptions of Kawasaki disease, this cohort had an 8-fold increase in
procalcitonin level, what suggests a particularly strong post-viral immunological reaction
to SARS-CoV-2 as compared with other viral agents.
59% of the patients were originally from sub-Saharan Africa or Caribbean islands, and
12% from Asia, suggesting possible genetic predisposition or travel-associated exposure.

Title: Acute heart failure in multisystem inflammatory syndrome in children (MIS-C)
in the context of global SARS-CoV-2 pandemic
Publisher: Circulation
Publication Date: May 17, 2020
URL: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.048360
Key Takeaway: Authors report a series of febrile pediatric patients with acute heart failure
potentially associated with SARS-CoV-2 infection and the multisystem inflammatory
syndrome in children (MIS-C) as defined by the US Centers for Disease Control. Children
may experience an acute cardiac decompensation due to severe inflammatory state following
SARS-CoV-2 infection (multisystem inflammatory syndrome in children - MIS-C).
Treatment with immune globulin appears to be associated with recovery of left ventricular
systolic function.

HEALTH WORKFORCE
Title: Introducing the “Corona Curtain”: an innovative technique to prevent airborne
COVID-19 exposure during emergent intubations
Publisher: Patient Safety in Surgery
Publication Date: May 13, 2020
URL: https://pssjournal.biomedcentral.com/track/pdf/10.1186%2Fs13037-020-00247-5
Key Takeaway: The new “Corona Curtain” was designed to improve the safety of ED staff
when performing urgent/emergent intubations during the current COVID-19 pandemic. The
concept can easily be adopted to other patient care areas, including perioperative and
intensive care units.

EPIDEMIOLOGY (FOCUS ON DC METRO AREA)
Title: Severe COVID-19 in Children and Young Adults in the Washington, DC
Metropolitan Region
Publisher: Journal of Pediatrics
Publication Date: May 2020
URL: https://www.jpeds.com/article/S0022-3476(20)30581-3/fulltext
Key Takeaway: 177 infected children and adolescents, including 44 hospitalized and
9 critically ill (3/15 4/30/2020). Twenty-five (25) percent of patients presenting with
symptoms required hospitalization and 5% required critical care. Children <1 year of age and
children/young adults >15 years of age each represented 32% (14/44) of all hospitalized
patients and combined total of 64% of hospitalizations (p=0.07). Adolescents and young
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adults > 15 years of age represented 66% (6/9) of critical care admissions (p=0.02).
Underlying medical conditions represented 27/44 (63%) of hospitalized patients: Asthma
(20%), neurologic disease (6%), diabetes (3%), obesity (2%), cardiac (3%), hematologic
(3%) and malignancy (1%). Many (134/177, 76%) came with respiratory symptoms, fever.
However, only 85/177 (48%) had both fever and respiratory symptoms. Co-infection was
uncommon (6%; ½ of these with entero /rhinovirus). One critically ill patient with Kawasaki
like syndrome. No deaths have been reported to date.

EPIDEMIOLOGY AND PUBLIC HEALTH
Title: The Time Sequences of Oral and Fecal Viral Shedding of Coronavirus Disease
2019 (COVID-19) Patients
Publisher: Gastroenterology
Publication Date: May 16, 2020
URL: https://www.sciencedirect.com/science/article/pii/S0016508520306636
Key Takeaway: Retrospective cohort study of 401 laboratory-confirmed COVID-19
patients -admitted to Shenzhen Third People's Hospital in China were included in this study.
Viral RNAs of SARS-CoV-2 were tested by quantitative RT-PCR in both the respiratory and
rectal specimens.
- Pediatric (< 18 years-old) patients possessed a positive rate of 56.67%, compared to
16.98% in adult (≥18 years-old) patients.
- 58 (11.8%) pairs were positive in both rectal and respiratory samples, 112 (21.7%) pairs
were positive in rectal while negative in respiratory samples, 40 (7.7%) pairs were
positive in respiratory while negative in rectal swabs.
- SARS-CoV-2 RNA in fecal samples remained for an unexpected long period, with
higher positive rate and higher viral load than the paired respiratory samples. The longest
duration observed was 43 days.
Note: Viral culture results needed to evaluate infectivity were not reported.

Title: Epidemiology, clinical course, and outcomes of critically ill adults with COVID19 in New York City: a prospective cohort study
Publisher: The Lancet
Publication Date: May 19, 2020
URL: https://doi.org/10.1016/S0140-6736(20)31189-2
Key Takeaway: This prospective observational cohort study of 1150 hospitalized patients
with Covid-19 in New York City documents the critical illnesses, laboratory markers, clinical
course, diagnoses and high frequency of invasive mechanical ventilation, extrapulmonary
organ dysfunction, and substantial in-hospital mortality.
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GOVERNMENT/POLICY UPDATES
Title: CDC Activities and Initiatives Supporting the COVID-19 Response and the
President’s Plan for Opening America Up Again.
Publisher: CDC
Publication Date: May 21, 2020
URL: https://www.cdc.gov/coronavirus/2019-ncov/downloads/php/CDC-ActivitiesInitiatives-for-COVID-19-Response.pdf
Key Takeaway: This document is the CDC guidance for reopening that was released on
May 21 and briefly summarizes public health activities that must be in place and
recommendations for different sectors for reopening.

Title: Summary of Recommendations to the ReOpen DC Advisory Group
Publisher: ReOpen DC Advisory Group/DC DOH
Publication Date: May 21, 2020
URL: https://coronavirus.dc.gov/reopendc
Key Takeaway: Summary of recommendations for reopening for different sectors
(businesses, healthcare, transportation, childcare/education, religious and government
services, etc.) at each stage of reopening specific for DC (and which GW must follow).

EMERGING CONVERSATIONS*
*This section aims to spread emerging ideas from the professional rumor mill, in an effort to
keep decision makers apprised of topics that are brewing. While this information may become
part of the COVID pedagogy, it currently represents non-scientific, non-evidence-based
propositions. Accordingly, we do not recommend incorporation into clinical guidelines.
Despite a documented spike in community spread of Covid-19 syndrome, Mayor Bowser says
DC may still reopen on May 29th. See: https://dcist.com/story/20/05/25/coronavirus-latestbowser-says-d-c-may-still-reopen-on-may-29/#bowsermay25

Are Pregnant Women at higher risk? In contrast to the recent paper reporting pathology
findings in placentas, many studies indicate good outcomes of pregnant patients.
https://www.medrxiv.org/content/10.1101/2020.05.08.20089268v1
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